NUPLAZID (pimavanserin tartrate)
ANTIPSYCHOTICS · PSYCHOSIS ASSOCIATED WITH PARKINSON'S DISEASE
ACADIA PHARMACE
Drug class
Selective serotonin 5-HT2A inverse agonists (SSIA)
Selective serotonin 5-HT2A inverse agonists (SSIAs) are a novel class of atypical antipsychotics characterized by preferential binding to and inactivation of serotonin 5-HT2A receptors. Read more about Selective serotonin 5-HT2A inverse agonists (SSIA)
2 drugs in this class 1 manufacturers
Drugs in Selective serotonin 5-HT2A inverse agonists (SSIA)
NUPLAZID (pimavanserin tartrate)
ANTIPSYCHOTICS · PSYCHOSIS ASSOCIATED WITH PARKINSON'S DISEASE
ACADIA PHARMACE
Filter & compare in the drug finder →
Opens the drug finder with Selective serotonin 5-HT2A inverse agonists (SSIA) preselected. Add indication or manufacturer filters there.
Selective serotonin 5-HT2A inverse agonists (SSIAs) are a novel class of atypical antipsychotics characterized by preferential binding to and inactivation of serotonin 5-HT2A receptors.
Unlike conventional and second-generation antipsychotics, they lack meaningful affinity for dopamine D2, muscarinic, histaminergic, or adrenergic receptors, suppressing basal serotonergic neurotransmission without provoking dopamine blockade.
Clinically exemplified by pimavanserin, this dopamine-sparing mechanism enables SSIAs to manage psychotic symptoms—specifically hallucinations and delusions—without deteriorating motor function.
Consequently, their primary therapeutic application is in Parkinson's disease psychosis, with additional investigation into other neurodegenerative and neuropsychiatric disorders.
-
nih.gov
Selective serotonin 5-HT2A inverse agonists (SSIAs) are a novel class of atypical antipsychotics characterized by preferential binding to and inactivation of serotonin 5-HT2A receptors
-
researchgate.net
Selective serotonin 5-HT2A inverse agonists (SSIAs) are a novel class of atypical antipsychotics characterized by preferential binding to and inactivation of serotonin 5-HT2A receptors Unlike conventional and second-generation antipsychotics, they lack meaningful affinity for dopamine D2, muscarinic, histaminergic, or adrenergic receptors, suppressing basal serotonergic neurotransmission without provoking dopamine blockade
-
nih.gov
Unlike conventional and second-generation antipsychotics, they lack meaningful affinity for dopamine D2, muscarinic, histaminergic, or adrenergic receptors, suppressing basal serotonergic neurotransmission without provoking dopamine blockade
-
nih.gov
Clinically exemplified by pimavanserin, this dopamine-sparing mechanism enables SSIAs to manage psychotic symptoms—specifically hallucinations and delusions—without deteriorating motor function
-
reallifepharmacology.com
Clinically exemplified by pimavanserin, this dopamine-sparing mechanism enables SSIAs to manage psychotic symptoms—specifically hallucinations and delusions—without deteriorating motor function
-
nih.gov
Consequently, their primary therapeutic application is in Parkinson's disease psychosis, with additional investigation into other neurodegenerative and neuropsychiatric disorders
-
nih.gov
Consequently, their primary therapeutic application is in Parkinson's disease psychosis, with additional investigation into other neurodegenerative and neuropsychiatric disorders
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.